L
Lyudmila Bazhenova
Researcher at University of California, San Diego
Publications - 215
Citations - 10761
Lyudmila Bazhenova is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 42, co-authored 170 publications receiving 7457 citations. Previous affiliations of Lyudmila Bazhenova include University of San Diego & University of California.
Papers
More filters
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele,Alexander Drilon,Alexander Drilon,Luis Paz-Ares,Salvatore Siena,Alice T. Shaw,Anna F. Farago,Collin M. Blakely,Takashi Seto,Byung Chul Cho,D. Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido-Laguna,Stephen V. Liu,Paul Conkling,Thomas John,Marwan Fakih,Darren Sigal,Herbert H. Loong,Gary L Buchschacher,Pilar Garrido,Jorge Nieva,Conor E. Steuer,Tobias Overbeck,Daniel W. Bowles,Elizabeth Fox,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann M. Johnson,Susan Eng,Timothy R. Wilson,George D. Demetri +38 more
TL;DR: Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.
Journal ArticleDOI
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood D. Goss,Chun-Ming Tsai,Frances A. Shepherd,Lyudmila Bazhenova,Jong Seok Lee,Gee-Chen Chang,Lucio Crinò,Miyako Satouchi,Quincy Chu,Toyoaki Hida,Ji-Youn Han,Oscar Juan,Frank Dunphy,Makoto Nishio,Jin-Hyoung Kang,Margarita Majem,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Tetsuya Mitsudomi +19 more
TL;DR: Osimertinib showed clinical activity with manageable side-effects in patients with EGFR Thr790Met-positive non-small-cell lung cancer and could be a suitable treatment for patients who have progressed on an EGFR tyrosine-kinase inhibitor.
Journal ArticleDOI
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon,Geoffrey R. Oxnard,Daniel Shao-Weng Tan,Herbert H. Loong,Melissa Lynne Johnson,Justin F. Gainor,Caroline E. McCoach,Oliver Gautschi,Benjamin Besse,Byoung Chul Cho,Nir Peled,Jared Weiss,Yu-Jung Kim,Yuichiro Ohe,Makoto Nishio,Keunchil Park,Jyoti D. Patel,Takashi Seto,Tomohiro Sakamoto,Ezra Rosen,Manisha H. Shah,Fabrice Barlesi,Philippe A. Cassier,Lyudmila Bazhenova,Filippo de Braud,Elena Garralda,Vamsidhar Velcheti,Miyako Satouchi,Kadoaki Ohashi,Nathan A. Pennell,Karen L. Reckamp,Grace K. Dy,Jürgen Wolf,Benjamin Solomon,Gerald Steven Falchook,Kevin Ebata,Michele Nguyen,Binoj Nair,Edward Y. Zhu,L. Yang,Xin Huang,Elizabeth Olek,S. Michael Rothenberg,Koichi Goto,Vivek Subbiah +44 more
TL;DR: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated.
Journal ArticleDOI
NCCN Guidelines ® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger,Douglas E. Wood,Wallace Akerley,Lyudmila Bazhenova,Hossein Borghaei,D.R. Camidge,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,M. Chris Dobelbower,Ramaswamy Govindan,Mark Hennon,Leora Horn,Thierry Jahan,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato G. Martins,Gregory A. Otterson,Jyoti D. Patel,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,Neelesh Sharma,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +35 more
TL;DR: New immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC are discussed, based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.